Welcome to our dedicated page for Biolinerx SEC filings (Ticker: BLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLineRx Ltd. (BLRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ and the Tel Aviv Stock Exchange. BioLineRx files annual reports on Form 20‑F and frequent current reports on Form 6‑K, which together document its financial performance, clinical progress and material corporate events.
Recent Form 6‑K filings referenced by the company include quarterly financial results for periods ended March 31, June 30 and September 30, 2025. These reports incorporate condensed consolidated interim financial statements and operating and financial reviews, giving detail on revenues from APHEXDA royalties, research and development expenses, general and administrative costs, and the company’s cash position and runway guidance.
Filings also cover transactional and strategic developments. For example, a September 29, 2025 Form 6‑K describes the joint venture agreement with Hemispherian AS and the asset transfer of GLIX1‑related intellectual property into a newly created company. The filing outlines ownership percentages, funding commitments, governance arrangements and rights related to additional assets in Hemispherian’s pipeline.
Other 6‑K submissions attach press releases on topics such as the USPTO Notice of Allowance for GLIX1 patents, as well as shareholder meeting results, including approvals of director elections, changes to authorized share capital, compensation policy updates and auditor appointments.
On Stock Titan, these BLRX filings are supplemented by AI‑powered summaries that explain the key points of each document in plain language. Users can quickly understand the implications of lengthy 20‑F and 6‑K reports, track changes in financial metrics over time, and identify disclosures related to clinical trials, licensing agreements, equity issuances and corporate governance. The page also links to information on insider and major shareholder activity when reported on applicable SEC forms.
BioLineRx Ltd. filed a Form 6-K highlighting a joint update with Hemispherian AS that the first patient has been dosed in a first-in-human, Phase 1/2a trial of GLIX1 for recurrent and progressive glioblastoma and other high-grade gliomas.
The study, conducted at leading U.S. cancer centers including NYU Langone Health, will initially enroll up to 30 patients in a Phase 1 dose-escalation stage to determine a maximum tolerated or recommended dose based on safety, pharmacokinetics/pharmacodynamics and preliminary efficacy. Initial Phase 1 data are anticipated in the first half of 2027.
GLIX1 is described as an oral, first-in-class small molecule designed to activate TET2 and selectively induce DNA damage in cancer cells, with strong preclinical activity and blood-brain-barrier penetration. A Phase 2a expansion is planned in newly diagnosed glioblastoma and selected other cancers, including combinations such as with PARP inhibitors.
BioLineRx Ltd. director Yan Shaoyu has filed an initial Form 3 insider report. The data shows no reported transactions, with buy, sell, acquire, and dispose counts all at zero. The filing also lists no derivative positions and no holding entries in this snapshot.
BioLineRx Ltd. director Sandra Panem filed an initial ownership report showing multiple employee stock options to buy Ordinary Shares. The options cover blocks such as 199,800 shares at an exercise price of $0.356 and 1,080,000 shares at $0.085, with expirations between 2026 and 2034.
Footnotes state that earlier grants from 2016 through 2024 are fully vested, while an October 1, 2024 grant left 856,200 options vested at appointment and 1,198,800 options scheduled to vest in seven equal quarterly installments, subject to her continued service.
BioLineRx Ltd. director Raphael Hofstein filed an initial ownership report showing he holds several employee stock options over the company’s ordinary shares. This Form 3 does not report new purchases or sales, but lists option grants previously awarded under the company’s 2003 Amended and Restated Share Incentive Plan.
The disclosed positions include options exercisable at prices such as $0.8370, $0.9200, and as low as $0.0520 per share, with expiration dates ranging from July 2026 to August 2034. Footnotes state that most grants are already fully vested, while a large grant covering 2,055,000 underlying shares at $0.0520 has 856,200 options vested and 1,198,800 scheduled to vest in seven equal quarterly installments, contingent on his continued service.
BioLineRx Ltd. director Dar Rami reported initial holdings of employee stock options over Ordinary Shares. The Form 3 shows several option grants with exercise prices between $0.052 and $0.085, expiring between 2032 and 2034, granted under the 2003 Amended and Restated Share Incentive Plan.
One grant over 2,055,000 underlying shares at an exercise price of $0.052 includes 856,200 options vested as of the appointment date, with the remaining 1,198,800 vesting in seven equal quarterly installments, subject to continued service.
BioLineRx Ltd. director Molcho Avraham filed an initial ownership report showing a portfolio of employee stock options to acquire Ordinary Shares. The filing lists multiple fully vested grants made between July 2016 and July 2024 under the 2003 Amended and Restated Share Incentive Plan, with exercise prices ranging from $0.052 to $0.920 per share and expirations between 2026 and 2034. One large grant covers 2,055,000 underlying shares at an exercise price of $0.052 per share, expiring in 2034, of which 856,200 options were vested on the October 1, 2024 grant date and the remaining 1,198,800 options vest in seven equal quarterly installments, subject to continued service.
BioLineRx Ltd. director Cohen Gal Avraham filed an initial ownership report detailing employee stock options over 2,055,000 underlying ordinary shares. These options carry an exercise price of $0.052 per share and expire on August 14, 2034.
The options were granted on October 1, 2024 under the company’s 2003 Amended and Restated Share Incentive Plan. As of the grant date, 856,200 options were vested, with the remaining 1,198,800 scheduled to vest in seven equal quarterly installments, subject to continued service. The filing reflects holdings only and does not report any purchases or sales.
BioLineRx Ltd. director Aharon Schwartz filed an initial ownership report showing direct holdings of 3,705,000 Ordinary Shares. He also holds multiple fully vested and time-vested employee stock options under the company’s 2003 Amended and Restated Share Incentive Plan, with exercise prices ranging from $0.052 to $0.92 per share and expirations extending through 2034. A large October 2024 grant covers 2,055,000 underlying Ordinary Shares, of which 856,200 were vested at appointment and the remaining 1,198,800 are scheduled to vest in seven equal quarterly installments, subject to continued service.
BioLineRx Ltd. filed an Amendment No. 1 to its Form 20-F for the fiscal year ended December 31, 2025. The amendment is limited to correcting the date referenced in the consent of its independent auditor, Kesselman & Kesselman, a member firm of PwC, filed as Exhibit 15.1.
Updated CEO and CFO certifications under Sections 302 and 906 of the Sarbanes-Oxley Act are included as new exhibits, as required for amendments. All other disclosures in the original annual report remain unchanged, and the amendment does not update events after the original filing.
BioLineRx Ltd. Chief Executive Officer Philip A. Serlin filed an initial ownership report detailing his equity position. He directly holds 5,131,800 Ordinary Shares and a series of employee stock options over additional Ordinary Shares with exercise prices ranging from $0.2640 down to $0.0450, expiring between 2026 and 2033. Several option grants are fully vested, while the most recent grant includes options that will vest in quarterly installments, subject to his continued service.